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Background: Arthritis pain is reported as one of the most common reasons for persons using medical herbal
cannabis in North America. “Severe arthritis” is the condition justifying legal use of cannabis in over half of all
authorizations in Canada, where cannabis remains a controlled substance. As champions for the care of persons
with arthritis, rheumatologists must be knowledgeable of treatment modalities both traditional and non-traditional,
used by their patients. As study of cannabinoid molecules in medicine is recent, we have examined the confidence
in the knowledge of cannabinoids expressed by Canadian rheumatologists.
Methods: The confidence of rheumatologists in their knowledge of cannabinoid molecules and mechanisms
relevant to rheumatology, and their ability to advise patients about cannabinoid treatments was recorded by an
online questionnaire circulated via email to the entire Canadian Rheumatology Association membership.
Results: Over three quarters of the 128 respondents lacked confidence in their knowledge of cannabinoid
molecules. While 45% of respondents believed there was no current role for cannabinoids in rheumatology patient
care, only 25% supported any use of herbal cannabis. With 70% never having previously prescribed or
recommended any cannabinoid treatment, uncertainty regarding good prescribing practices was prevalent.
Concerns about risks of cannabis use were in line with the current literature.
Conclusions: Rheumatologists lacked confidence in their knowledge of cannabinoid molecules in general and in
their competence to prescribe any cannabinoid for rheumatic complaints. In line with this uncertainty, there is
reticence to prescribe cannabinoid preparations for rheumatology patients. Guidance is required to inform
rheumatologists on the evidence regarding cannabinoids.
Keywords: Cannabinoids, Rheumatic diseases, Physician knowledgeBackground
Patients with rheumatic conditions almost universally ex-
perience pain with impact on quality of life. Chronic
rheumatic pain is complex to treat in view of a dynamic
interaction of various molecules and nerve pathways, all
subject to nervous system plasticity. Drugs to treat pain
offer mostly a modest effect, with use limited by adverse* Correspondence: mary-ann.fitzcharles@muhc.mcgill.ca
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article, unless otherwise stated.effects. In the absence of a cure for rheumatic pain, pa-
tients will continue to seek remedies to reduce symptoms.
Phytocannabinoids obtained from the plant Cannabis
sativa have given symptom relief over centuries. With at
least 66 different cannabinoid molecules in the plant Can-
nabis sativa, delta-9-tetrahydrocannabinol and cannabidiol
are the best studied [1]. Musculoskeletal pain is commonly
cited as a medical reason for using herbal cannabis, a dried
preparation of cannabis sativa, in North America [2]. As
the champions for rheumatic patient care, rheumatologists
should be knowledgeable of current evidence for use of
the category of cannabinoids, either pharmacological prep-
arations termed synthetocannabinoids or the plant-derivedtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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to effectively advise patients.
With increasing patient advocacy to access herbal
cannabis in the new millennium, the debate about
decriminalization and possible legalization of cannabis
has straddled the line between recreational and thera-
peutic use, with resulting regulatory changes in Canada
and several states in the US. In Canada, cannabis has
been legally available for medical purposes since 2001,
following creation of an access program regulated by
Health Canada. As of June 2013, almost 2/3 of the
32,000 Canadians who hold an authorization to possess
medical cannabis had “severe arthritis” as the medical
condition justifying use [3].
Recent changes in Canadian regulations will require
health care professionals to prescribe herbal cannabis
similarly to other prescriptions drugs. This accrued role
for health care practitioners, likely to be followed in
other countries, is controversial and has stimulated de-
bate in the medical community [4,5]. To formally exam-
ine rheumatologists’ confidence about cannabinoids in
general, and pertinence for use in rheumatic conditions,
Canadian rheumatologists were surveyed.
Methods
In March 2013, the entire Canadian Rheumatology As-
sociation (CRA) membership, approximately 510 rheu-
matologists, was invited via email to participate in a
survey examining current knowledge and perceptions re-
garding cannabinoid use in rheumatology patients. The
survey was available online from March 26th 2013 to
April 5th 2013. A second reminder by email was sent to
encourage non respondents. Data were collected once
the survey was closed. The Canadian Rheumatology As-
sociation did not require ethical approval to carry out
surveys of its members and ethical approval is not re-
quired for this type of study under Canadian law.
The 19-question survey comprised 3 sections. The first
obtained demographic information, years and location of
practice, type of practice (academic, community or pri-
vate), and age and gender. The second addressed respon-
dents’ current perception of knowledge of cannabinoids
including phyto-, syntheto-, and endocannabinoids, as well
as respondents’ belief whether there is a role for canna-
binoids in rheumatology practice. The third addressed
physicians’ response regarding interactions with pa-
tients requesting access to herbal cannabis or those in
whom other pain treatments had failed.
Perception of knowledge of cannabinoids was assessed
according to confidence (very confident; confident; some-
what confident; not confident). Respondents reported
whether they had previously recommended trials of canna-
binoid preparations to treat rheumatic pain, and whether
they would consider a cannabinoid trial in the future.Questions specifically pertaining to herbal cannabis were
as follows: Do you believe there is a role for the use of
medical cannabis in treating rheumatic diseases; how
would you react if a patient asks about the use of medical
cannabis; have you ever recommended a trial of medical
cannabis or would you recommend a trial in the future; in
the event of recommending medical cannabis, what is
your confidence in writing a prescription regarding dos-
age, frequency of use and method of administration, and if
a prescription was written what would be the starting
dose, maximum dose, dose frequency and method of ad-
ministration. Narrative responses were obtained for the
following questions: variables needing consideration in pa-
tients requesting medical cannabis; advice given regarding
precautions when using medical cannabis; patient charac-




The survey was sent to all 510 members of the CRA,
with 128 (25%) responding. Demographic information
for the respondents is shown in Table 1. The majority of
respondents were over the age of 35, 57% were male,
most had been in practice for over 10 years and were al-
most entirely practicing in urban areas. Over two thirds
reported that their practice was academic or a combin-
ation of academic and private practice.
Physician knowledge of cannabinoids and therapeutic
considerations
Three quarters of respondents were not confident about
their current knowledge of cannabinoid molecules (phyto,
syntheto, and endocannabinoids), with only 18% reporting
being somewhat confident. Lack of confidence in know-
ledge of the physiology of the endocannabinoid system in
health and disease was reported by two thirds of respon-
dents (see Table 2).
Almost half of respondents (45%) believed that there is
currently no therapeutic role for use of any cannabinoid
in the management of rheumatic diseases, whereas 25%
believed there was a role for both pharmacologic canna-
binoids and medical (herbal) cannabis, 25% believed
there was a role for pharmacologic cannabinoids only,
and 5% for medical (herbal) cannabis only.
Seventy percent of respondents had never previously
recommended any form of cannabinoid treatment for
patients, with 17% and 13% respectively having previ-
ously recommended pharmacologic preparations only,
or pharmacologic and/or herbal preparations. Similarly,
60% of respondents would not currently recommend a
trial of any cannabinoid preparation, with 20% each agree-
able to recommend a trial of pharmacologic cannabinoids
only, or pharmacologic and/or medical (herbal) cannabis.
Table 1 Demographic information for 128 respondents,





n = 128 n = 95 N = 33
Gender, out of 127 n (%)
Male 72 (57) 48 (51) 24 (73)
Female 55 (43) 46 (49) 9 (27)
Age, out of 127 n (%)
35 or younger 16 (13) 16 (17) 0 (0)
36–49 52 (41) 38 (40) 14 (42)
50 and over 59 (46) 40 (43) 19 (58)
Years in practice, out of 127 n (%)
< 10 35 (28) 30 (32) 5 (15)
10–24 57 (45) 42 (45) 15 (46)
25 or over 35 (28) 22 (23) 13 (39)
Practice location n (%)
Urban 119 (93) 87 (92) 32 (97)
Rural 9 (7) 8 (8) 1 (3)
Practice type n (%)
Academic 46 (36) 33 (35) 13 (39)
Academic/private 37 (29) 28 (30) 9 (27)
Community hospital/private 24 (19) 19 (20) 5 (15)
Private 21 (16) 15 (16) 6 (18)
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Seventy per cent of respondents believe that there is cur-
rently no role for medical (herbal) cannabis in the man-
agement of rheumatic diseases, with only 16 (13%) having
ever previously recommended a trial. Over 90% of respon-
dents were not confident in writing a prescription for
medical (herbal) cannabis when required to indicate dos-
ing, frequency, and method of administration. Eleven (9%)
respondents indicated a starting dose of medical (herbal)
cannabis, ranging from 2 puffs twice a day, to 0.5 g-3 g/
day, with 9 (7%) identifying a ceiling dose, with the
highest ceiling dose recommended as 5 g/day. A single
dosing regimen was most commonly suggested by 6Table 2 Questions assessing confidence in 128 respondents
Survey question
“Do you feel confident regarding your current knowledge of the
endocannabinoid system in health and disease?” (out of 126)
Very con
“Do you feel confident regarding your current knowledge of the
cannabinoid to, syntheto, and endocannabinoids)?”
Very con
“How confident are you to write a prescription for medical cannabis
indicating dosage, frequency of use, and method of administration?”
(out of 127)
Very con(5%), with the rest suggesting a twice or three times a
day dosing, with equal numbers recommending oral or
inhaled administration. Reservations were stated re-
garding inhalation, but respondents acknowledged that
herbal cannabis is mostly smoked. About half of respon-
dents did not distinguish between medical (herbal) can-
nabis and pharmacologic cannabinoids with regard to
efficacy (56%), side effects (53%) and treatment indica-
tions (60%).
When respondents described factors that require con-
sideration for patients requesting medical (herbal) can-
nabis, the following were the most common variables
identified by 74 respondents: previous substance abuse by
50, failed other treatments by 25, specific diagnosis by 15,
mental health status by 14, patient age by 11, psychosocial
issues and comorbidities by 9 each. Other variables men-
tioned less frequently included disease severity, smoking
history, drug interactions, previous recreational use, doc-
tor/patient relationship, diversion potential, and patient
gender and occupation.
Forty respondents listed precautions that would be com-
municated to patients when prescribing medical (herbal)
cannabis as follows: work and driving/operating machin-
ery by 11, overuse/abuse and diversion by 11, addiction
risk by 6, concurrent medication/substance use by 4, risks
associated with smoking and cognitive impairment by 3
each, same precautions as for opioids by 2, and with-
drawal, social support, cancer risk, weight gain as well as
lack of scientific knowledge by 1 each. Eleven of the 40 ad-
mitted not knowing any precautions to communicate to
patients.
When asked to list barriers that would prevent them
from prescribing medical (herbal) cannabis, 47 respon-
dents listed the following elements: History/potential of
drug abuse or addiction by 27, mental health issues by 9,
medical health including lack of clear diagnosis or non-
severity of pain complaint by 9, and poor patient/phys-
ician relationship including history of non-compliance
by 8. Other barriers noted less frequently were alcohol
abuse, not having tried conventional treatments, smok-
ing, criminal behaviour, diversion potential, risks related
to driving and operating heavy machinery, and previous
recreational use, amongst others.Response
fident (0) Confident (11) Somewhat confident (29) Not confident (86)
fident (0) Confident (9) Somewhat confident (24) Not confident (95)
fident (1) Confident (1) Somewhat confident (10) Not confident (115)
Fitzcharles et al. BMC Musculoskeletal Disorders 2014, 15:258 Page 4 of 6
http://www.biomedcentral.com/1471-2474/15/258Grouping of respondents according to confidence in
knowledge of cannabinoid molecules (results shown in
Table 3)
When respondents were divided into those who re-
ported confidence (n = 33) vs. non-confidence (n = 95)
in their knowledge of cannabinoid molecules, 48% vs.
23% respectively believed that there is a role for medical
(herbal) cannabis in the management of rheumatic dis-
eases. Of those reporting confidence, 33% had previously
recommended a trial of pharmacologic cannabinoids
only, 27% a trial of medical (herbal) cannabis, whereas
39% had never recommended one or the other. In non-
confident respondents, rates were respectively 12%, 7%,
and 81%. One third vs. two thirds of confident vs. non-
confident respondents would not recommend either
pharmacologic cannabinoids or medical (herbal) canna-
bis in the future.Table 3 Stratification of 128 respondents according to confid
cannabinoid molecules























Confidence level regarding writing a medical cannabis prescription (dose, fre
Expressed confidence
Not confident
Did not answerWhen conventional treatments have failed, 42% vs. 23%
of confident vs. not confident respondents would write a
prescription of medical (herbal) cannabis, whereas only
9% vs. 2% respectively would write a prescription for med-
ical (herbal) cannabis on the basis of patient request. Even
amongst confident respondents, less than one third in-
dicated confidence in writing a prescription for medical
(herbal) cannabis when required to specify dosage, fre-
quency of use, and method of administration.
Discussion
This study demonstrates lack of confidence by rheumatol-
ogists in their knowledge of cannabinoids in general and in
their ability and competence to prescribe any cannabinoid,
either pharmacological or herbal preparations for rheum-
atic pain. In line with this uncertainty, there is an overall
reticence in providing prescriptions for any cannabinoidence and non-confidence in knowledge regarding
Not confident Confident P value
n = 95 N = 33
s? n (%)
21 (22) 10 (30) NS
22 (23) 16 (48) .008
50 (53) 7 (21) .0006
2 (2) 0 (0)
11 (12) 11 (33) .007
7 (7) 9 (27) .006
77 (81) 13 (39) < .0001
15 (16) 10 (30) NS
13 (14) 12 (36) .009
65 (68) 11 (33) .0008
2 (2) 0 (0)
tional treatments? n (%)
22 (23) 14 (42) .043
70 (74) 17 (52) .029
3 (3) 2 (6)
egardless of previous
2 (2) 3 (9) NS
90 (95) 28 (85) NS
3 (3) 2 (6)
quency) n (%)
3 (3) 9 (27) .0002
92 (97) 23 (70) < .0001
0 (0) 1 (3)
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should raise two important concerns. Firstly, as cannabi-
noids are known to have a physiologic role in the human
organism, albeit not yet fully defined, this shortfall in basic
knowledge of a system with pertinence in rheumatic con-
ditions indicates a knowledge gap between current science
and the clinician. Secondly, in the setting of increased pub-
lic demand for access to herbal cannabis for chronic condi-
tions, there exists a mismatch between patient needs and
advocacy,and physician knowledge [6]. This lack of know-
ledge likely stems from the paucity of clinical information
regarding use of cannabinoids in rheumatology practice
[7]. This societal groundswell is however reflected by regu-
latory bodies worldwide that are considering the merits of
legalizing herbal cannabis.
The current controversy about cannabinoid treatments
centers primarily on the role of herbal cannabis (“medical
marijuana”) used as a therapeutic modality, particularly in
the context of rheumatic pain management. To date there
is not a single controlled clinical study that has examined
efficacy or safety of herbal cannabis in the rheumatic dis-
eases [7]. Pharmacological cannabinoids such as nabilone
are legal and readily available in many countries, and re-
search on their safety and efficacy, while still modest, is
considerably more advanced than research on herbal can-
nabis. Furthermore, pharmacological cannabinoids have a
more reliable and safe delivery system, whereas adminis-
tration of herbal cannabis, which is often smoked, presents
an uncontrolled delivery system with potential harm due
to inhaled toxic substances. There is however increasing
evidence for harm when herbal cannabis is used, including
acute psychomotor effects leading to accidents, and long
term effects on cognition, respiratory function and risk of
addiction.
The ubiquitous nature of the endocannabinoid system
raises questions as to the exact function of this system
in health and disease, with preclinical studies contribut-
ing to the understanding of physiologic mechanisms, but
with limited experience in the clinical arena. Contrary to
popular belief, the cannabinoid effects are not only con-
fined to the nervous system and pain pathways, but have
effects on inflammation and joint damage [8]. This high-
lights a promising role for cannabinoids in the manage-
ment of various rheumatic conditions, but with need for
sound basic science and clinical study.
The overriding principle for effective rheumatic pain
management is symptom relief with maintained func-
tion, rather than palliation [9]. Although numerous
non-pharmacologic and pharmacologic strategies are
available, pain treatments remain suboptimal [10]. Treat-
ment of musculoskeletal pain is a common reason for
use of herbal cannabis. For example, 80% of users in a
pain clinic in the US reported myofascial pain, and up to
one third of persons in two population studies in the UKand Australia reported using cannabis for treatment of
arthritis pain [2,11,12]. In the state of Colorado, with 2%
of the population registered to use medical herbal can-
nabis, pain although not further specified, is the reason
for use in over 90% of persons [13].
The absence of any recommendation for use of any
cannabinoid, and particularly herbal cannabis for treat-
ment of arthritis pain in current treatment guidelines
likely contributes to the low rate of confidence expressed
by participants of this survey. It is therefore understand-
able that rheumatologists report limited previous experi-
ence in prescribing any form of cannabinoid molecule,
with less than a quarter willing to recommend herbal
cannabis. Among confident respondents, 27% had rec-
ommended a trial of herbal cannabis, compared to only
7% of non-confident respondents. In the absence of clin-
ical evidence to support a role for herbal cannabis in the
management of rheumatic pain, rheumatologists’ reluc-
tance to prescribe is entirely appropriate. It also follows
that those who are most confident in their knowledge of
cannabinoids are also more likely to prescribe herbal
cannabis.
Even those who would suggest use of herbal cannabis
and were confident in their knowledge of cannabinoids
expressed lack of knowledge of dosing and methods of
administration. The results of this study are in line with
concerns expressed by family physicians in Colorado [13].
Similar to the opinions of Canadian rheumatologists, only
19% of family physicians who responded to a question-
naire thought that medical marihuana should be recom-
mended to patients. This is of particular interest as
Colorado is the US state with the greatest per-capita per-
sons registered to possess herbal cannabis for medicinal
use. Therefore both these surveys of North American phy-
sicians demonstrate an important gap between public and
legislative perceptions and the comfort of the medical
community in advising patients.
In Canada, the medical cannabis access program gov-
erned by Health Canada was repealed and replaced by
the Marihuana for Medical Purposes Regulations in
April 2014, with health care practitioners bearing full
responsibility for providing a prescription for herbal
cannabis. If physicians are to prescribe herbal cannabis,
medical ethics and deontology require that they be com-
petent regarding the prescribed treatment (molecules,
dosage, safety, etc.), which is not the case as demon-
strated by this survey. This is particularly concerning as
“severe arthritis” is cited as the most common diagnosis
for persons holding an authorization to possess cannabis
in Canada [3].
There is therefore an evident disconnect between
patients’ needs and good medical practice regarding the
prescription of cannabinoid molecules in general. This
disconnect likely explains the “awkward” strain put on
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subject of herbal cannabis is broached, with concerns
that new regulations may further exacerbate this strenu-
ous conversation [5].
Although this study reflects the beliefs of rheumatolo-
gists from a single country, it is noteworthy that Canada
currently has liberal regulations regarding medical herbal
cannabis access. Our study is also limited by the response
rate of 25%, however this rate is in keeping with the usual
response rates of surveys in general, and reasons for non-
response may be explained by apathy, lack of knowledge
or disagreement with cannabinoid use for rheumatic
conditions.
Conclusions
The results of this survey, whereby the greater proportion
of respondents expressed insecurity regarding cannabinoid
knowledge, has highlighted the need for more in depth
evaluation of both phyto- and synthetocannabinoids in
rheumatic disease management, as well as education for
the health care community. Further research should
address factors such as the specific cannabinoid molecules
that could be used, dosing, method of administration,
side-effects, and drug interactions, as well as the specific
rheumatic conditions for which cannabinoids could be
prescribed. However, even in the absence of substantial
scientific proof, the health care community will require
guidance regarding the use of cannabinoids in the treat-
ment of rheumatic conditions in view of growing public
advocacy and patient requests.
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